# Revolution Medicines, Inc.: overview

RVMD · Nasdaq · CIK 1628171 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rvmd.md) · [Financials](/companies/rvmd/financials.md) · [Filings](/companies/rvmd/filings.md) · [Insiders](/companies/rvmd/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-071563.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Feb 25, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-071563).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-122303.md) | [0.0 d](/filings/0001193125-26-071563.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.94)](/filings/0001193125-25-266923.md) | not reported | [(1.13)](/filings/0001193125-26-208969.md) | [(1.31)](/filings/0001193125-26-335104.md) | [(1.61)](/filings/0001193125-25-266923.md) | not reported | [(2.29)](/filings/0001193125-26-208969.md) | [(3.06)](/filings/0001193125-26-335104.md) |
| Free cash flow | $m | [(134) d](/filings/0001193125-25-266923.md) | [(140) d](/filings/0001193125-26-071563.md) | [(198)](/filings/0001193125-26-208969.md) | [(229) d](/filings/0001193125-26-335104.md) | [(211) d](/filings/0001193125-25-266923.md) | [(276) d](/filings/0001193125-26-071563.md) | [(356)](/filings/0001193125-26-208969.md) | [(390) d](/filings/0001193125-26-335104.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [29.4](/filings/0000950170-24-020145.md) | [35.4](/filings/0000950170-25-027736.md) | [11.6](/filings/0001193125-26-071563.md) | [0.0](/filings/0001193125-26-071563.md) | [0.0](/filings/0001193125-26-071563.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(639.7%)](/filings/0000950170-24-020145.md) | [(730.0%)](/filings/0000950170-25-027736.md) | [(4207.1%)](/filings/0001193125-26-071563.md) | not reported | not reported |
| Net margin | % | [(636.6%)](/filings/0000950170-24-020145.md) | [(703.0%)](/filings/0000950170-25-027736.md) | [(3768.3%)](/filings/0001193125-26-071563.md) | not reported | not reported |
| Diluted EPS | $ per share | [(2.57)](/filings/0000950170-24-020145.md) | [(3.08)](/filings/0000950170-25-027736.md) | [(3.86)](/filings/0001193125-26-071563.md) | [(3.58)](/filings/0001193125-26-071563.md) | [(5.95)](/filings/0001193125-26-071563.md) |
| Free cash flow | $m | [(154)](/filings/0000950170-24-020145.md) | [(235)](/filings/0000950170-25-027736.md) | [(358)](/filings/0001193125-26-071563.md) | [(568)](/filings/0001193125-26-071563.md) | [(914)](/filings/0001193125-26-071563.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rvmd/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-26 | [Mancini Anthony](/insiders/2124509.md) | See Remarks, Officer | Sale (S) | 2,310 | $186.99 | $431.9k | [Form 4](/filings/0001193125-26-436459.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.56bn | 13,695,790 |  | Added +2,483,084 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $2.54bn | 13,550,796 |  | Reduced −54,000 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $2.28bn | 12,200,422 |  | Added +3,736,108 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $2.14bn | 11,443,357 |  | Added +1,888,000 |
| [Darwin Global Management, Ltd.](/funds/1839209.md) | 2026-06-30 | $2.05bn | 10,629,822 |  | Added +8,418,804 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $2.01bn | 10,736,145 |  | Not compared |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.70bn | 9,088,661 |  | Added +726,377 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.55bn | 8,294,855 |  | Added +792,232 |
| [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $1.42bn | 7,601,087 |  | Unchanged |
| [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $1.19bn | 6,361,323 |  | Reduced −294,380 |

## Recent filings

[All 857 filings](/companies/rvmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 16:32 ET | [8-K](/filings/0001628171-26-000004.md) | 2.03 New direct financial obligation; 8.01 Other events | 0001628171-26-000004 |
| 2026-09-01 | 06:00 ET | [8-K](/filings/0001193125-26-377362.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-377362 |
| 2026-08-26 | 13:33 ET | [8-K](/filings/0001193125-26-366931.md) | 8.01 Other events | 0001193125-26-366931 |
| 2026-08-05 | 16:10 ET | [10-Q](/filings/0001193125-26-335104.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335104 |
| 2026-08-05 | 16:05 ET | [8-K](/filings/0001193125-26-335039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335039 |
| 2026-06-22 | 08:00 ET | [8-K](/filings/0001193125-26-276718.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-276718 |
| 2026-05-06 | 16:10 ET | [10-Q](/filings/0001193125-26-208969.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208969 |
| 2026-05-06 | 16:05 ET | [8-K](/filings/0001193125-26-208918.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208918 |
| 2026-04-27 | 17:30 ET | [DEF 14A](/filings/0001193125-26-182453.md) | Proxy statement, period 2026-06-18 | 0001193125-26-182453 |
| 2026-04-17 | 17:16 ET | [8-K](/filings/0001193125-26-161800.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-161800 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071563.md), filed Feb 25, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1628171
- Tickers: RVMD, RVMDW
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:38 ET. No prices; not investment advice.